Table 2.
Evolution of quality indicators as formulated by EUSOMA prospectively evaluated between 2003 and 2011 (data for first semester breast clinic Sint Augustinus Hospital, Antwerp).
| Outcome measure | 2003 | 2011 | p-level | Minimum Standard |
| Positive preoperative cyto/histological diagnosis | 59.7% | 88.3% | 0.0001 | 80% |
| Operated invasive carcinoma for which histological type, grading, ER/PR status, stage and size were recorded | 94.1% | 96.4% | NS | 90% |
| Operated non invasive carcinoma for which size, histological type and grading are recorded | 72% | 100% | NS | 90% |
| More then 9 lymph nodes removed when axillary lymph node dissection performed (sampling excluded) | 85.6% | 86.4% | NS | 85% |
| Postoperative radiotherapy in non-metastatic invasive carcinoma treated with breast conserving surgery | 98% | 97.3% | NS | 90% |
| Breast conserving surgery in invasive carcinoma with total size up to 30 mm (including DCIS component) | 62% | 88% | 0.001 | 70% |
| Breast conserving treatment for in situ carcinoma up to 20 mm diameter | 43.8% | 88% | 0.0016 | 70% |
| Ductal carcinoma in situ without axillary dissection | 85.7% | 97.1% | NS | 80% |
| Hormonotherapy in endocrine sensitive invasive carcinoma | 84.8% | 93.4% | 0.0002 | 80% |
| Adjuvant chemotherapy in ER negative (pT1c+ or N+) invasive carcinoma | 72% | 97.1% | 0.0280 | 80% |
N: number; ER: estrogen receptor; PR: progesterone receptor.